Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OCE-213
- Development stage
- Unknown
- Lead developer
- Ocean Biomedical
01
Overview
OCE-213 is a drug candidate being developed by Ocean Biomedical, a biopharmaceutical company focused on oncology, fibrosis, and malaria treatments. While Ocean Biomedical has a diversified pipeline with various drug and vaccine candidates, specific details regarding the mechanism of action, primary indication, or development phase of OCE-213 are not publicly disclosed. The company aims to translate scientific discoveries into treatments for unmet medical needs, leveraging partnerships with research institutions. Ocean Biomedical became a publicly traded company through a merger with Aesther Healthcare Acquisition Corp. to fund its drug development efforts.
Beyond the preview
Go deeper on OCE-213.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OCE-213.